Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)
Executive Summary
Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis is part of Shire's plan to dramatically increase neuroscience revenues – but it won't launch the drug outside the US for some time.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Shire Continues To Grow HAE Franchise With Takhzyro, As Hemophilia Takes A Hit
Approved in late August, the HAE prophylaxis drug has already yielded $51m in US revenues, with EU approval expected by year-end. The HAE franchise is a growth leader for Shire, despite peaks and valleys due to supply issues.
Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?